Alnylam Pharmaceuticals (ALNY) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on ...

Biopharmaceutical stock Alnylam Pharmaceuticals (NASDAQ:ALNY) is riding a tsunami of hope that a treatment for a rare heart condition receives Food & Drug Administration approval. Although it has several drugs already on the market, the biopharma is not yet profitable.But if Alnylam can gain expedited approval from the FDA for its RNA interference drug vutrisiran, that could change quickly. Alnylam stock soared 31% on positive Phase 3 trial news and continued rising afterward. Getting vutrisiran, which is m ...

Could Alnylam Pharmaceuticals (NASDAQ:ALNY) become a household name in 2024? At the very least, the company should be well known in the medical community. If you like to wager small amounts of money on biotechnology stocks, then you really ought to consider Alnylam Pharmaceuticals stock.As we’ll discuss in a moment, Alnylam Pharmaceuticals didn’t start off 2024 with perfect financials. However, a recent announcement indicates a breakthrough moment for Alnylam Pharmaceuticals and, potentially, for some heart ...

Intuitively, the case for biotechnology-related investments comes across rather obviously: the concept of healthcare should be a permanent one. And because of this permanence, the expected market value of the ecosystem should be massive. Grand View Research estimates that it would be worth $3.88 trillion by 2030. Still, the opportunistic investor may want to consider cheap biotech stocks.It comes down to adding more pieces on the table. You can always elect the high-flying names that command rich multiple p ...

UKRAINE - 2021/05/27: In this photo illustration, the Alnylam Pharmaceuticals logo seen on a ... [+] smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesAlnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a significant rise of 60% in a week. This can be attributed to positive data from a late-stage clinical trial ...

Alnylam Pharmaceuticals (ALNY) hit a new 52-week high on Monday after it reported positive top-line results from a late-stage study evaluating Amvuttra (vutrisiran), an investigational RNAi therapeutic, for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy. The stock jumped 34.5% in response to the success of the study.Please note that Amvuttra is already approved in the United States for the treatment of adult patients with polyneuropathy of hereditary ATTR amyloidosis. It is a ...

Key TakeawaysAlnylam Pharmaceuticals announced a Phase-3 study of its treatment for a rare heart condition showed a significant reduction in deaths and recurrent cardiovascular events.The biopharmaceutical company said it would be seeking regulatory approval later this year, including asking the Food and Drug Administration for a priority review.The news sent shares of Alnylam soaring over 31% in early trading Monday. Shares of Alnylam Pharmaceuticals (ALNY) skyrocketed over 31% in early trading Monday afte ...

Follow Invezz on Telegram , Twitter , and Google News for instant updates >Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug. Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.Shares of the biopharmaceutical company are now trading at a year-to-date high of $220.  Why is it significant for Alnylam Pharmaceuticals stock?Copy link to sectionVutrisiran de ...

Alnylam Pharmaceuticals (ALNY) shares ended the last trading session 5.3% higher at $165.70. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.4% gain over the past four weeks.The sudden rise in the stock price has likely been driven by the growing optimism of investors regarding Amvuttra’s (vutrisiran) potential to earn increasing revenues for the company. The drug, approved for treating adult patients with polyne ...

Editor's note: Seeking Alpha is proud to welcome SA's Undercovered Dozen Series as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » cassp/E+ via Getty Images Introduction There's lots to like in our first weekly edition of The "Undercovered" Dozen. We'll be presenting ideas that were published during June 1st - 6th. So f ...